FDA Determines Regulatory Review Period for Patent Extension of Human Drug Product MULTAQ

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for patent extension for human drug products, including MULTAQ, and is publishing this notice as required by law. The FDA made this determination due to patent extension applications submitted to the Director of Patents and Trademarks, Department of Commerce.